NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells

被引：2
|
作者：
Li, Yangguang [1 ,2 ]
Wang, Fangyu [1 ,2 ]
Lu, Li [1 ,2 ]
Zhu, Fen [1 ,2 ]
Huang, Shengjian [3 ]
Nomie, Krystle [3 ]
Zhang, Liang [3 ]
Yang, David T. [2 ,4 ]
Huang, Wei [4 ]
Kahl, Brad S. [5 ]
Safe, Stephen [6 ]
Wang, Michael [3 ]
Rui, Lixin [1 ,2 ]
机构：
[1] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI 53792 USA
[2] Univ Wisconsin, Sch Med & Publ Hlth, Carbone Canc Ctr, Madison, WI 53792 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[4] Univ Wisconsin, Dept Pathol & Lab Med, Sch Med & Publ Hlth, Madison, WI 53792 USA
[5] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA
[6] Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA
来源：
BLOOD CANCER JOURNAL | 2017年 / 7卷
关键词：
NUCLEAR RECEPTORS; CANCER; APOPTOSIS; SURVIVAL; BCL-2; BTK;
D O I：
10.1038/s41408-017-0005-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Bis-indole derived nuclear receptor 4A1 (NR4A1) antagonists inhibit TGFβ-induced invasion of embryonal rhabdomyosarcoma cells
    Shrestha, Rupesh
    Mohankumar, Kumaravel
    Safe, Stephen
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (08): : 2495 - +
  • [42] The stress-response molecule NR4A1 resists ROS-induced pancreatic β-cells apoptosis via WT1
    Zong, Chen
    Qin, Dandan
    Yu, Cong
    Gao, Peng
    Chen, Jicui
    Lu, Sumei
    Zhang, Yuchao
    Liu, Yuantao
    Yang, Yingfeng
    Pu, Zeqing
    Li, Xia
    Fu, Yuchang
    Guan, Qingbo
    Wang, Xiangdong
    CELLULAR SIGNALLING, 2017, 35 : 129 - 139
  • [43] The STAT3 inhibitor WP1066 synergizes with vorinostat to induce apoptosis of mantle cell lymphoma cells
    Lu, Kang
    Chen, Na
    Zhou, Xiang-xiang
    Ge, Xue-ling
    Feng, Li-li
    Li, Pei-pei
    Li, Xin-yu
    Geng, Ling-yun
    Wang, Xin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 464 (01) : 292 - 298
  • [44] Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells
    Lee, Seung-Cheol
    Shestov, Alexander A.
    Guo, Lili
    Zhang, Qian
    Roman, Jeffrey C.
    Liu, Xiaobin
    Wang, Hong Y.
    Pickup, Stephen
    Nath, Kavindra
    Lu, Pin
    Hofbauer, Samuel
    Mesaros, Clementina
    Wang, Y. Lynn
    Nelson, David S.
    Schuster, Stephen J.
    Blair, Ian A.
    Glickson, Jerry D.
    Wasik, Mariusz A.
    MOLECULAR CANCER RESEARCH, 2019, 17 (06) : 1365 - 1377
  • [45] Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis
    Mohammad Roufarshbaf
    Mohsen Javeri
    Vajihe Akbari
    Payman Hosseini Matin
    Pegah Farrokhi
    Erfan Sadeghi
    Zahra Heidari
    Azadeh Moghaddas
    DARU Journal of Pharmaceutical Sciences, 2022, 30 : 367 - 378
  • [46] A Novel Triplet of Alisertib Plus Ibrutinib Plus Rituximab Is Active in Mantle Cell Lymphoma
    Subramani, Baskaran
    Conway, Patrick J.
    Al-Khinji, Aisha
    Zhang, Kun
    Pandey, Ritu
    Mahadevan, Daruka
    CANCERS, 2024, 16 (24)
  • [47] Specific Inhibition of β-Catenin in Jeko-1 Mantle Cell Lymphoma Cell Line Decreases Proliferation and Induces Apoptosis
    He, Jinshui
    Huang, Yiqun
    Weng, Jianmin
    Xiao, Liyun
    Weng, Kaizhi
    Ma, Xudong
    MEDICAL SCIENCE MONITOR, 2015, 21 : 2218 - 2224
  • [48] Ibrutinib: A Review of Its Use in Patients with Mantle Cell Lymphoma or Chronic Lymphocytic Leukaemia
    Kim, Esther S.
    Dhillon, Sohita
    DRUGS, 2015, 75 (07) : 769 - 776
  • [49] Ibrutinib in association with venetoclax for the treatment of mantle-cell lymphoma: a multicenter case series
    Fabbri, Alberto
    Cencini, Emanuele
    Congiu, Angela Giovanna
    Miglino, Maurizio
    Rigacci, Luigi
    Bocchia, Monica
    AMERICAN JOURNAL OF BLOOD RESEARCH, 2020, 10 (06): : 355 - 359
  • [50] Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis
    Roufarshbaf, Mohammad
    Javeri, Mohsen
    Akbari, Vajihe
    Matin, Payman Hosseini
    Farrokhi, Pegah
    Sadeghi, Erfan
    Heidari, Zahra
    Moghaddas, Azadeh
    DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 30 (02) : 367 - 378
12345